"alpha-Synuclein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synuclein that is a major component of LEWY BODIES that plays a role in neurodegeneration and neuroprotection.
| Descriptor ID |
D051844
|
| MeSH Number(s) |
D12.776.631.860.500 D12.776.637.500
|
| Concept/Terms |
alpha-Synuclein- alpha-Synuclein
- alpha Synuclein
- Non-AB Component of AD Amyloid Protein
- Non AB Component of AD Amyloid Protein
|
Below are MeSH descriptors whose meaning is more general than "alpha-Synuclein".
Below are MeSH descriptors whose meaning is more specific than "alpha-Synuclein".
This graph shows the total number of publications written about "alpha-Synuclein" by people in this website by year, and whether "alpha-Synuclein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 5 | 7 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 4 | 0 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 9 | 0 | 9 |
| 2019 | 5 | 3 | 8 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 3 | 6 |
| 2022 | 2 | 1 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder. Ann Neurol. 2025 Sep; 98(3):482-491.
-
Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits. eNeuro. 2025 Apr; 12(4).
-
Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease. Cell Rep. 2025 Mar 25; 44(3):115355.
-
Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics. ACS Chem Neurosci. 2024 11 06; 15(21):3915-3931.
-
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
-
Olfactory deficit and gastrointestinal dysfunction precede motor abnormalities in alpha-Synuclein G51D knock-in mice. Proc Natl Acad Sci U S A. 2024 Sep 24; 121(39):e2406479121.
-
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024 Aug 01; 147(8):2668-2679.
-
Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of a-synuclein inclusions. Neuron. 2024 Sep 04; 112(17):2886-2909.e16.
-
Downregulation of Protease Cathepsin D and Upregulation of Pathologic a-Synuclein Mediate Paucity of DNAJC6-Induced Degeneration of Dopaminergic Neurons. Int J Mol Sci. 2024 Jun 18; 25(12).
-
Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.